Circ Cardiovasc Interv

Slides:

Advertisements

Similar presentations

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Advertisements

Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: A comparison of three-year survival after coronary.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Non–ST-Segment Elevation Acute Coronary.

Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Asymptomatic Individuals With a Positive Family.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent.

LEADER trial: Primary Outcome

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

Complex Coronary intervention

ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.

Copyright © 2009 American Medical Association. All rights reserved.

Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting.

Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery.

Circ Cardiovasc Interv

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

Circ Cardiovasc Interv

Sex-Related Differences in Fractional Flow Reserve–Guided Treatment

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Qual Outcomes

ISAR‐PEBIS (Paclitaxel‐Eluting Balloon Versus Conventional Balloon Angioplasty for In‐Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Circ Cardiovasc Imaging

Catheter-Based Treatment of Coronary Artery Disease

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Baseline characteristics of patients

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

American Heart Association Presented by Dr. Julinda Mehilli

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Flow Diagram of the Trial Selection Process

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs

Characteristics of included studies

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

FIELD: Primary outcome

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs

Pamela E. Scott et al. JACC 2018;71:

Javier Escaned et al. JCIN 2018;11:

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

Circ Cardiovasc Interv Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionClinical Perspective by Ilka Ott, Stefanie Schulz, Julinda Mehilli, Stefanie Fichtner, Martin Hadamitzky, Katharina Hoppe, Tareq Ibrahim, Steffan Martinoff, Steffen Massberg, Karl-Ludwig Laugwitz, Josef Dirschinger, Markus Schwaiger, Adnan Kastrati, Albert Schömig, and Circ Cardiovasc Interv Volume 3(5):408-413 October 19, 2010 Copyright © American Heart Association, Inc. All rights reserved.

Flow diagram of the trial. Ilka Ott et al. Circ Cardiovasc Interv. 2010;3:408-413 Copyright © American Heart Association, Inc. All rights reserved.

Six-month event-free survival (events: death, recurrent MI, infarct-related artery revascularization, and stroke) in the epoetin (closed line) and the placebo group (dotted line). Six-month event-free survival (events: death, recurrent MI, infarct-related artery revascularization, and stroke) in the epoetin (closed line) and the placebo group (dotted line). HR indicates hazard ratio. Ilka Ott et al. Circ Cardiovasc Interv. 2010;3:408-413 Copyright © American Heart Association, Inc. All rights reserved.